China's CDE approved Ascentage Pharma's olverembatinib for a global Phase III trial in SDH-deficient GIST patients.
Ascentage Pharma's novel drug candidate, olverembatinib, has been approved by China's CDE for a global Phase III trial in SDH-deficient gastrointestinal stromal tumor (GIST) patients who failed prior treatment. The study's results will support a future NDA for olverembatinib, an orally-available, third-generation TKI. This marks a significant milestone for Ascentage Pharma in solid tumor clinical development.
June 11, 2024
4 Articles